CancerScreenDx™ is a multi-cancer early detection test that can detect over 110 types of cancer through a single blood draw. This test is unique in that it can detect many types of cancer that are not commonly screened by routine cancer biomarkers tests. When a cancer signal is detected, the CancerScreenDx™ test predicts the origin of the cancer signal with high accuracy to help guide the next steps to diagnosis. Using the CancerScreenDx™ test alongside existing screening tools is expected to improve early cancer detection for patients at an elevated risk of cancer, such as those aged 40 or older. This will help to identify cancer at an earlier stage, which can lead to improved outcomes for patients and reduced costs of treatment.
healthcare, medical, oncology
The ability to detect over 110 types of cancer, many of which are not covered by routine cancer biomarker tests, makes this tool invaluable in identifying cancers that might otherwise go undetected until they are more advanced.
Detecting cancer at an earlier stage generally leads to better treatment outcomes. Early-stage cancers are often more treatable and may require less aggressive treatments than advanced cancers, improving patient quality of life and survival rates.
When the test detects a cancer signal, it can predict the origin of the cancer with high accuracy. This feature is crucial in guiding healthcare providers toward the most appropriate subsequent diagnostic tests and interventions, potentially speeding up the time to diagnosis and treatment.
Early detection often means less expensive treatment, which can significantly reduce healthcare costs. By identifying cancers early, when they are typically less expensive to treat, the test could lead to overall cost savings in cancer care.
Single blood draw, simplifies the screening process, making it more accessible and less invasive for patients.
All tests are conducted locally in our ISO 15189 certified lab, with results delivered within 7-14 working days from sample receipt.